MetaCap

Beta Bionics (BBNX) vs Bioventus (BVS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bioventus (BVS) has outperformed Beta Bionics (BBNX) over the past year, gaining 36.5% versus a loss of 57.5%. Beta Bionics is the larger company by market cap ($726.3 million vs $676.5 million), about 1.1 times the size. Bioventus converts more of its revenue into profit, with a net margin of 4.0% versus -73.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBNX-57.48%BVS+36.46%
+120%+19%-81%
Nov 21, 20251 yearNov 20, 2026
BBNX-43.89%BVS-7.49%
+45%-11%-68%
Jan 27, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBNX versus BVS key metrics
MetricBBNXBVS
Share price$13.36$9.88
Market cap$726.34M$676.53M
1-day change+0.30%-0.70%
YTD return-56.15%+32.80%
1-year return-57.48%+36.46%
5-year return—-21.02%
P/E ratio (TTM)—12.20
Forward P/E—11.13
EPS (TTM)$-1.83$0.81
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$100.25M$568.09M
Revenue growth (YoY)+53.94%-0.91%
Net income (latest FY)$-73.20M$22.73M
Gross margin55.40%68.33%
Operating margin-71.50%9.50%
Net margin-73.02%4.00%
52-week high$32.71$15.89
52-week low$8.80$7.02
Distance from 52-week high-59.16%-37.83%
Analyst consensusbuynone
Avg. price target upside+87.87%+68.02%
Average volume1.21M536.81K
Shares outstanding54.37M68.47M
Employees420960
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BVS has outperformed BBNX by 93.9 percentage points over the past year.
  • Bioventus is more profitable, keeping 4.0 cents of every revenue dollar as net income versus -73.0 cents for Beta Bionics.
  • Beta Bionics grew revenue faster in its latest fiscal year (+53.94% vs -0.91%).

About Beta Bionics

BBNX stock →

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.

Health Care · Medical/Dental Instruments · 420 employees

About Bioventus

BVS stock →

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.

Health Care · Medical/Dental Instruments · 960 employees

BBNX vs BVS FAQ

Which is bigger, Beta Bionics or Bioventus?

Beta Bionics (BBNX) is larger, with a market capitalization of $726.34M compared with $676.53M for Bioventus (BVS).

Which stock has performed better over the past year, BBNX or BVS?

BVS returned +36.46% over the past 12 months, compared with -57.48% for BBNX (price return, excluding dividends). Past performance does not predict future results.

Are Beta Bionics and Bioventus in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons